INTRODUCTION
============

The number of liver transplantations being performed each year is ultimately limited by graft availability. Despite the increasing demand for orthotopic liver transplantation (OLT), supply of deceased donor organs has persisted as the barrier for patients awaiting transplantation. In 2013, there were 6256 liver transplantations performed in the USA. That same year, 10,143 patients were added to the waiting list and 3002 either died or became too sick to undergo transplantation \[[@B1]\]. This discrepancy has pushed the transplant community to explore novel ways to increase the donor pool.

Procurement of marginal organs, living donor transplantation and split liver transplantation (SLT) are three innovative ways that the transplant community has tried to meet the expanding demand for more organs. In 1988, the first descriptions of SLT were reported \[[@B2], [@B3]\]. Initially employed by splitting an adult liver into a left lateral segment for a child and right trisegment allograft for an adult recipient, SLT decreased the pediatric wait list without taking grafts away from the adult recipient population. Despite initial concerns, splitting donor allografts for pediatric and adult patients has been shown to be safe and resourceful \[[@B4]-[@B7]\]. Although SLT is a clear solution to the pediatric graft deficit and has decreased wait list times for pediatric recipients \[[@B8]-[@B10]\], the role for adult donor pool expansion with full-right-full-left split liver transplantation (FRFLSLT) has only been recently explored.

Just as pediatric-adult SLT was controversial in its infancy; there is concern that FRFLSLT has inferior results when compared to adult/child SLT or whole liver transplant (WLT). Early reports of success with FRFLSLT have been published, however, numbers have been limited \[[@B11]-[@B17]\]. These studies are heavily reliant on donor and recipient selection, and investigation into the large scale applicability of FRFLSLT has been lacking. To address the paucity of information available, this study assessed the outcomes of FRFLSLT by comparing full-right (FR), full-left (FL),and whole liver (WL) grafts in adults using United Network for Organ Sharing (UNOS) standard transplant analysis and Standard Transplant Analysis and Research (STAR).

MATERIAL AND METHODS
====================

The data were collected from the UNOS as reported between 1998 and 2010. Patients with WL, FR, or FL hemiliver allograft were included in the analysis. Pediatric patients and SLT using right trisegment allografts were excluded from the analysis. Means and SDs were given for continuous variables as they were normally distributed, and percentages were provided for categorical variables. To control for multiple pairwise comparisons between graft types, p values from *Student's t*tests for continuous variables, and χ^2^ for categorical variables, were considered statistically significant at α=0.017 (Bonferroni correction). Patient and graft survival were compared between the graft types using Kaplan-Meier survival analysis. The log-rank test was used to test for equality of survival distributions between the curves for each graft type.

Propensity analysis \[[@B18]\] was conducted to adjust for differences in patient characteristics between liver graft recipients when examining the association between graft type and outcome. A multiple logistic regression model predicting whole graft was used to obtain propensity scores. The model included the covariates: recipient and donor age, MELD score, length of stay (LOS), days waiting for transplant, donor and recipient weight, cold ischemia, donor risk index (DRI), sex, and hepatocellular carcinoma (HCC). The propensity scores (probability of WL) were divided into quintiles to illustrate the similarities in characteristics between the graft types after propensity matching. Patients with extreme scores (0 or \>0.97) were excluded from the stratified and adjusted analyses, as it was not possible to match graft recipients by propensity for WL graft at these extreme values. Multivariable Cox proportional hazards models were fit to predict graft failure and mortality. The final adjusted models included only statistically significant predictors (p\<0.05) and propensity score. The final graft failure and mortality models included the covariates age of donor, MELD, LOS, and donor weight; and the mortality model also adjusted for recipient age and HCC. All analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

We found that during 1998--2010, a total of 768 adult patients underwent SLT using FR or FL allografts; 651 FR, and 117 FL. At the same time period, 83,313 adult patients received WL allograft ([Fig 1](#F1){ref-type="fig"}). The demographic and clinical characteristics of donors and recipients are shown in [Table 1](#T1){ref-type="table"}. Donor age was similar in FR and FL while it was significantly higher for WL. Donor weight was higher in the FL and WL groups when compared to FR (77 and 76 *vs*. 72 kg, respectively). Transplant recipient weight was highest for WL patients (82 kg) when compared to FR (72 kg) and FL (69 kg). Those with WL had less time on the liver waiting list than FR and FL (215 *vs*. 344 and 231 days, respectively). FL recipients had shorter cold ischemic time than FR and WL (7.7 *vs*. 8.8 and 8.6 hours, respectively) and were less likely to be male (42% *vs*. 48% and 64%, respectively). MELD scores were similar for FR and FL (18 and 19, respectively) and significantly lower when comparing FR to WL (21). DRI scores were comparable in FR and FL groups (3.9) and significantly higher than WL (2.7).
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###### 

Demographics of adult liver transplant patients from 1988--2010 (n=84,081). Figures are either mean (SD) or percent

  -------------------------------------------------------------------------------------------------------------------
  Variables                                    WL (1)\       FR (2)\       FL (3)\      p value               
                                               (n=83,313)    (n=651)       (n=117)                            
  -------------------------------------------- ------------- ------------- ------------ ---------- ---------- -------
  Age (yrs)                                    51 (11)       52 (11)       51 (12)      0.65       0.74       0.60

  Donor age (yrs)                              38 (17)       24 (10)       26 (11)      \<0.0001   \<0.0001   0.17

  MELD score                                   21 (9.2)      18 (8.1)      19 (9.3)     \<0.0001   0.12       0.34

  Length of stay post-transplantation (days)   21 (43)       19 (22)       21 (19)      0.29       0.98       0.04

  Days on liver waiting list                   215 (373)     344 (498)     231 (302)    \<0.0001   0.65       0.02

  Donor weight (kg)                            76 (19)       72 (15)       77 (18)      \<0.0001   0.36       0.001

  Recipient weight at registration (kg)        82 (20)       72 (17)       69 (19)      \<0.0001   \<0.0001   0.05

  Total cold ischemic time (hrs)               8.6 (4.5)     8.8 (4.5)     7.7 (3.7)    0.41       0.05       0.01

  DRI                                          2.7 (0.8)     3.9 (0.8)     3.9 (0.9)    \<0.0001   \<0.0001   0.31

  Follow-up time (days)                        1638 (1660)   1471 (1309)   1092 (992)   0.01       0.0004     0.003

  Male                                         64%           48%           42%          \<0.0001              

  Non-HCC                                      90%           88%           92%          0.06                  

  Re-transplantation                           8.5%          10%           13%          0.08                  
  -------------------------------------------------------------------------------------------------------------------

The unadjusted patient survival of all graft typesis shown in [Figure 2A](#F2){ref-type="fig"}, which suggests a trend toward better allograft survival after FR and WL compared to FL. The 5-year survival rates for FR, WL, and FL were 74%, 71%, and 67%, respectively. However, there was no statistically significant difference between the distribution of survival by graft types (p=0.07). Similarly, when comparing Kaplan-Meier curves between graft types with respect to allograft survival, the FL recipients appear to have the poorest long-term survival with a 5-year survival rate of 58%, while that of FR was 66% and WL was 64% ([Fig 2B](#F2){ref-type="fig"}). The differences between the curves were not statistically significant.
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Propensity scores were obtained for patients using multiple logistic regression predicting WL transplant. The c-statistic for the model was 0.99, which illustrated the model discriminated well. The matched patients were divided into quintiles of propensity for WL graft. After stratifying by propensity quintile, most of the differences in characteristics between recipients of different graft types were no longer statistically significant ([Table 2](#T2){ref-type="table"}). This allowed analysis of outcomes based on allograft type, thereby reducing selection bias based on donor and recipient characteristics. Propensity adjusted analysis ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}) showed no significant difference in allograft or patient survival between graft types. Both FR and WL were less likely to have graft failure or death when compared to FL, but the adjusted hazard ratio estimates were not significantly different.

###### 

Characteristics of liver transplant patients both unadjusted and adjusted for propensity quintile (n=1438

                           Unadjusted                             Quintile 1 (0.005--0.546)             Quintile 2 (0.547--0.850)             Quintile 3(0.851--0.937)               Quintile 4 (0.9373--0.963)            Quintile 5 (0.9631--0.975)                                                                                                             
  ------------------------ -------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------- ------------------------------------- ------------------------------------ ----- ----- ----- ----- ----- ------------------------------------ ----- ----- ----- ----- ------ -----
  Mean age                 52                                     52                                    52                                    52                                     52                                    53                                   52    51    54    52    52    41[\*](#TFN1){ref-type="table-fn"}   52    54    44    54    52     55
  Mean donor age           28                                     23\*                                  25                                    14                                     21[\*](#TFN1){ref-type="table-fn"}    21[\*](#TFN1){ref-type="table-fn"}   26    25    26    26    28    31                                   31    33    39    30    35     34
  Mean MELD                19                                     18                                    19                                    17                                     18                                    18                                   18    18    18    19    20    16                                   19    17    33    20    21     24
  Mean LOS                 18                                     18                                    20                                    18                                     17                                    16                                   19    19    24    17    17    21                                   18    12    30    20    16     18
  Mean LOS total           24                                     21                                    27                                    20                                     19                                    27                                   22    25    27    22    20    21                                   20    17    33    30    19     28
  Mean days wait           362                                    381                                   263                                   323                                    419                                   277                                  351   360   326   394   289   204                                  388   325   77    323   172    124
  Mean donor weight (kg)   83                                     73[\*](#TFN1){ref-type="table-fn"}    80                                    55                                     71[\*](#TFN1){ref-type="table-fn"}    78[\*](#TFN1){ref-type="table-fn"}   82    74    83    84    78    87                                   86    75    87    85    83     70
  Mean weight (kg)         76                                     72[\*](#TFN1){ref-type="table-fn"}    70[\*](#TFN1){ref-type="table-fn"}    66                                     70                                    72                                   72    74    67    77    80    72                                   78    75    71    78    78     64
  Mean cold isch. (hrs)    7.7                                    8.4[\*](#TFN1){ref-type="table-fn"}   7.2                                   8.3                                    8.7                                   7.5                                  7.8   7.8   7     7.7   8.1   7                                    7.6   9.1   5     7.6   8.1    8.1
  Mean DRI                 3.4                                    3.9[\*](#TFN1){ref-type="table-fn"}   3.8[\*](#TFN1){ref-type="table-fn"}   3.9                                    4.1[\*](#TFN1){ref-type="table-fn"}   4[\*](#TFN1){ref-type="table-fn"}    3.6   3.7   3.6   3.4   3.6   3.5                                  3.4   3.6   3.6   3.2   3.5    3.6
  Male (%)                 56[\*\*](#TFN2){ref-type="table-fn"}   49                                    42                                    37                                     42                                    35                                   51    54    52    60    50    57                                   65    73    50    52    83     20
  Non-HCC (%)              78                                     81                                    88                                    93[\*\*](#TFN2){ref-type="table-fn"}   78                                    93                                   81    82    76    76    92    86                                   78    80    100   76    83     100
  Re-transplantation (%)   5.6                                    6.1                                   12                                    11[\*\*](#TFN2){ref-type="table-fn"}   3.4                                   13                                   4.3   8.6   10    8.2   7.7   14                                   4.1   13    25    4     17.0   0
  Infection (%)            16                                     14                                    27                                    15                                     10                                    43                                   29    17    0     9.7   0     50                                   6.3   50    0     26    0      0

p\<0.017 WL vs. column

p\<0.05 over all groups

###### 

Risk of graft failure (n=1438)

  ----------------------------------------------------------------------
                HR[\*](#TFN3){ref-type="table-fn"} (95% CI)\   p value
                (WL n=1032, FR n=329, FL n=77)                 
  ------------- ---------------------------------------------- ---------
  FR *vs*. FL   0.68 (0.44--1.1)                               0.08

  WL *vs*. FL   0.74 (0.48--1.1)                               0.17
  ----------------------------------------------------------------------

HR: Hazard ratio

###### 

Risk of mortality (n=1438

  ----------------------------------------------------------------------
                HR[\*](#TFN4){ref-type="table-fn"} (95% CI)\   p value
                (WL n=1032, FR n=329, FL n=77)                 
  ------------- ---------------------------------------------- ---------
  FR *vs*. FL   0.77 (0.46--1.3)                               0.32

  WL *vs*. FL   0.87 (0.52--1.5)                               0.60
  ----------------------------------------------------------------------

HR: Hazard ratio

DISCUSSION
==========

SLT for two adult patients usually consists in the generation of a full-right graft (FRG, including segments V--VIII) and a full-left graft (FLG, including segments I--IV) \[[@B11]-[@B17]\]. Conversely, conventional SLT produces an extended right graft (ERG, including segments I, IV--VIII) and a left lateral segment (LLS) graft (including segments II and III), which classically benefit one adult and one pediatric recipient \[[@B8]-[@B10]\]. Although a few small single-center series have reported acceptable results with FRFLSLT \[[@B11]-[@B17]\], the outcomes obtained with this technique are generally worse than with WLT or living-donor liver transplantation \[[@B19]\]. As a result, FRFLSLT is not yet considered a standard procedure \[[@B20]-[@B23]\].

We report a series of SLTs for two adult recipients performed at US centers. Although unadjusted results of SLT using FL allografts in adults were inferior to FR, propensity matched analysis showed comparable allograft and patient survival. This experience showed that FRFLSLT can be safely applied in adult patients with acceptable outcomes being anticipated.

The use of propensity scores to create a risk-adjusted, demographically matched cohort based on allograft status (FL *vs*. FR) is an advantage of our study. Propensity scores reduce the entire collection of observed background characteristics to a single variable that appropriately summarizes that characteristics \[[@B18]\]. This step allowed a straight forward analysis of whether the FL or FR groups have enough overlap with respect to observed background covariates, to allow a true assessment of the effect of allograft type status on outcomes. The two groups in our propensity-matched cohort were virtually identical with respect to different background characteristics.

In the face of the severe organ shortage and high waiting list mortality in the adult population, every effort should be made to improve the utilization and outcomes of SLT in adults. If the FRFLSLT procedure is managed correctly, the advantages conferred by a younger donor population, two liver allografts should translate into better allograft and patient survival rates. The negative impacts of both higher recipient MELD scores and prolonged cold ischemic times (CIT) observed in deceased donor WLT are most probably amplified in the SLT group and should be taken into account. SLT represents a potentially underutilized resource in the USA. Factors such as high recipient MELD score and extended CIT may have negative effects on results in SLT and therefore, deter surgeons from performing this procedure. A different allocation system for these grafts that takes into consideration CIT and recipient MELD score should be considered \[[@B23]\].

A limitation of this study is its being a retrospective analysis of UNOS data. We recognize both potential advantages and limitations of such a large national database. The large sample size provides sufficient power to detect meaningful risk factors that may be missed by single-center studies. However, as with any analysis utilizing the UNOS database, our conclusions rely on the assumption that there is no systematic bias generated by reporting error or missing data. The groups are obviously unequal in size and selection criteria for one or the other procedure are not known. However, the primary endpoint for this analysis was allograft and patient survival, which is reliably captured in the UNOS database. Residual or unmeasured confounders that could impact allograft and patient survival include surgical technique and skill level, differences in immunosuppression protocols, the fat content/quality of the allografts, and center-specific practices. Other important determinants of success with SLT such as recipient and donor selection, choice of RL *vs* FL graft, graft weight and quality, surgical details, techniques employed to alleviate small-for-size syndrome, center and surgeon volume/experience were not available in the database. Biliary complications are done well captured in the database either.

Second, we did not have much data on the donor and the quality or size of the allograft. Third, the study did not look at the potential impact of the portal inflow and the hepatic vein outflow modulation in smaller grafts. Fourth, we were not able to analyzed center-specific outcomes. There is a size difference between FR (n=651) and FL (n=117). This would be due to the fact that some of FLs were used in a child or been discarded.

In summary, FRFLSLT in adults can expand the donor pool and provide reasonable outcomes in two adults using FR and FL hemiliver allografts.
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